An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

April 30, 2004

Study Completion Date

March 31, 2007

Conditions
Migraine Headache
Interventions
DRUG

Aricept (donepezil hydrochloride)

Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.

Trial Locations (4)

10550

Elkind Headache Center, Mount Vernon

19046

The Clinical Trial Center, LLC, Jenkintown

60614

Diamond Headache Clinical, Chicago

65804

Clinvest/Headache Care Center, Springfield

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT01146509 - An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis | Biotech Hunter | Biotech Hunter